Syndax Pharmaceuticals (SNDX) Short Interest Ratio & Short Volume $12.48 -0.24 (-1.89%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.60 +0.12 (+0.99%) As of 08/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Syndax Pharmaceuticals Short Interest DataSyndax Pharmaceuticals (SNDX) has a short interest of 23.69 million shares. This marks a -0.75% decrease in short interest from the previous month. The short interest ratio (days to cover) is 10.9, indicating that it would take 10.9 days of the average trading volume of 2.48 million shares to cover all short positions.Current Short Interest23,690,000 sharesPrevious Short Interest23,870,000 sharesChange Vs. Previous Month-0.75%Dollar Volume Sold Short$218.18 millionShort Interest Ratio10.9 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares86,140,000 sharesPercentage of Shares Shorted27.50%Today's Trading Volume2,853,978 sharesAverage Trading Volume2,484,140 sharesToday's Volume Vs. Average115% Short Selling Syndax Pharmaceuticals? Sign up to receive the latest short interest report for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSNDX Short Interest Over TimeSNDX Days to Cover Over TimeSNDX Percentage of Float Shorted Over Time Syndax Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202523,690,000 shares $218.18 million -0.8%N/A10.9 $9.21 6/30/202523,870,000 shares $223.42 million +8.5%28.9%10.4 $9.36 6/15/202522,000,000 shares $225.50 million -4.9%26.7%10 $10.25 5/31/202523,140,000 shares $244.59 million +6.5%28.3%10.7 $10.57 5/15/202521,730,000 shares $194.48 million +0.3%26.5%9.4 $8.95 4/30/202521,660,000 shares $306.49 million +2.3%N/A9.8 $14.15 4/15/202521,170,000 shares $239.86 million +9.4%25.9%9.8 $11.33 3/31/202519,360,000 shares $237.74 million +2.9%23.7%9.1 $12.28 3/15/202518,820,000 shares $243.72 million -2.0%23.0%8 $12.95 2/28/202519,200,000 shares $300.29 million -10.9%23.5%7.7 $15.64 Get the Latest News and Ratings for SNDX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/202521,550,000 shares $321.53 million -2.9%26.3%9.1 $14.92 1/31/202522,200,000 shares $314.57 million -0.8%N/A8.8 $14.17 1/15/202522,380,000 shares $286.46 million +5.0%N/A10.2 $12.80 12/31/202421,310,000 shares $281.72 million +30.3%N/A10.7 $13.22 12/15/202416,360,000 shares $227.89 million +13.6%N/A9.1 $13.93 11/30/202414,400,000 shares $240.77 million +35.9%N/A9.7 $16.72 11/15/202410,600,000 shares $167.80 million -0.6%N/A7.7 $15.83 10/31/202410,660,000 shares $201.05 million +1.4%N/A11.2 $18.86 10/15/202410,510,000 shares $207.57 million +4.3%N/A10.7 $19.75 9/30/202410,080,000 shares $194.04 million +4.2%N/A10 $19.25 9/15/20249,670,000 shares $184.89 million +1.9%N/A9.2 $19.12 8/31/20249,490,000 shares $195.02 million +0.6%N/A9 $20.55 8/15/20249,430,000 shares $188.22 million +9.8%N/A8.8 $19.96 7/31/20248,590,000 shares $194.99 million +0.8%N/A7.8 $22.70 7/15/20248,520,000 shares $207.72 million +2.2%N/A8.3 $24.38 6/30/20248,340,000 shares $171.22 million -15.9%N/A8.1 $20.53 6/15/20249,920,000 shares $199.49 million +2.8%N/A9.8 $20.11 5/31/20249,650,000 shares $185.96 million -3.8%N/A9.1 $19.27 5/15/202410,030,000 shares $220.06 million -0.8%N/A9.6 $21.94 4/30/202410,110,000 shares $213.62 million +5.3%N/A9.4 $21.13 4/15/20249,600,000 shares $207.55 million -0.2%N/A8.3 $21.62 3/31/20249,620,000 shares $228.96 million +15.5%N/A8.2 $23.80 3/15/20248,330,000 shares $195.92 million -8.4%N/A6.9 $23.52 2/29/20249,090,000 shares $213.07 million +5.7%N/A6.1 $23.44 2/15/20248,600,000 shares $194.96 million -1.0%N/A5.8 $22.67 1/31/20248,690,000 shares $178.06 million No ChangeN/A5.8 $20.49 1/15/20248,690,000 shares $193.27 million +3.7%N/A5.4 $22.24 12/31/20238,380,000 shares $181.09 million -19.0%N/A4.7 $21.61 12/15/202310,340,000 shares $214.76 million +1.1%N/A4.8 $20.77 11/30/202310,230,000 shares $170.28 million -3.7%N/A5.4 $16.65Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 11/15/202310,620,000 shares $159.94 million +6.4%N/A6.2 $15.06 10/31/20239,980,000 shares $140.52 million +17.4%N/A6.1 $14.08 10/15/20238,500,000 shares $101.92 million +12.1%N/A5.7 $11.99 9/30/20237,580,000 shares $110.06 million -0.1%N/A6 $14.52 9/15/20237,590,000 shares $131.76 million +9.1%N/A9.8 $17.36 8/31/20236,960,000 shares $128.83 million -2.8%N/A8.8 $18.51 8/15/20237,160,000 shares $132.03 million +7.7%N/A8.4 $18.44 7/31/20236,650,000 shares $141.78 million +12.1%N/A7.4 $21.32 7/15/20235,930,000 shares $125.42 million +3.3%N/A6.8 $21.15 6/30/20235,740,000 shares $120.14 million +2.5%N/A6.5 $20.93 6/15/20235,600,000 shares $119.45 million -10.0%N/A5.9 $21.33 5/31/20236,220,000 shares $124.21 million -2.7%N/A6.7 $19.97 5/15/20236,390,000 shares $135.15 million -2.0%N/A7.4 $21.15 4/30/20236,520,000 shares $133.99 million -5.2%N/A7.9 $20.55 4/15/20236,880,000 shares $137.60 million -9.8%N/A8.6 $20.00 3/31/20237,630,000 shares $161.15 million +12.4%N/A9.5 $21.12 3/15/20236,790,000 shares $151.42 million +13.4%N/A8.9 $22.30 2/28/20235,990,000 shares $151.85 million +8.5%N/A7 $25.35 2/15/20235,520,000 shares $143.46 million +0.6%N/A6.8 $25.99 1/31/20235,490,000 shares $157.56 million +0.6%N/A6.5 $28.70 1/15/20235,460,000 shares $143.65 million -14.3%N/A6.4 $26.31 12/30/20226,370,000 shares $162.12 million +22.5%N/A7.3 $25.45 12/15/20225,200,000 shares $125.84 million +17.7%N/A6.1 $24.20 11/30/20224,420,000 shares $105.90 million +5.7%N/A5.8 $23.96 11/15/20224,180,000 shares $91.46 million +2.7%N/A6 $21.88 10/31/20224,070,000 shares $93.45 million -9.2%N/A5.9 $22.96 10/15/20224,480,000 shares $105.41 million +0.9%9.4%6.7 $23.53 9/30/20224,440,000 shares $106.69 million -3.5%9.3%6.7 $24.03 9/15/20224,600,000 shares $113.02 million No Change9.6%7.2 $24.57 8/31/20224,600,000 shares $108.61 million +0.4%9.7%7 $23.61 8/15/20224,580,000 shares $113.31 million +5.1%9.6%7.1 $24.74 7/31/20224,360,000 shares $88.81 million +2.6%9.2%6.6 $20.37 7/15/20224,250,000 shares $80.92 million -24.8%9.2%6.8 $19.04 6/30/20225,650,000 shares $108.71 million -4.2%12.3%9.6 $19.24 6/15/20225,900,000 shares $95.76 million -0.7%12.8%10 $16.23 5/31/20225,940,000 shares $98.01 million -6.5%13.0%10.4 $16.50 5/15/20226,350,000 shares $89.60 million -1.6%13.9%10.9 $14.11 4/30/20226,450,000 shares $108.17 million +5.9%14.3%11.5 $16.77 4/15/20226,090,000 shares $110.47 million +9.1%13.5%11.1 $18.14 3/31/20225,580,000 shares $96.98 million -9.6%12.3%10.1 $17.38 3/15/20226,170,000 shares $99.21 million +18.9%13.8%11.6 $16.08 2/28/20225,190,000 shares $80.91 million +5.3%12.2%8.7 $15.59 2/15/20224,930,000 shares $81.69 million +17.1%11.6%8.7 $16.57 1/31/20224,210,000 shares $68.79 million +25.3%10.0%7.7 $16.34 1/15/20223,360,000 shares $60.78 million No Change7.5%5.8 $18.09 12/31/20213,360,000 shares $73.55 million -5.4%N/A6 $21.89 12/15/20213,550,000 shares $67.34 million +12.0%8.0%5.8 $18.97 11/30/20213,170,000 shares $50.62 million -6.8%7.4%5.8 $15.97 11/15/20213,400,000 shares $60.83 million -45.8%8.0%6.3 $17.89 10/29/20216,270,000 shares $121.95 million -1.0%14.6%11.6 $19.45Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 10/15/20216,330,000 shares $117.67 million -9.1%14.7%13.1 $18.59 9/30/20216,960,000 shares $133.01 million -11.0%16.2%13.8 $19.11 9/15/20217,820,000 shares $151.40 million -5.2%18.2%15.7 $19.36 8/31/20218,250,000 shares $144.29 million +2.7%19.2%17.9 $17.49 8/13/20218,030,000 shares $127.76 million -2.0%18.8%17.5 $15.91 7/30/20218,190,000 shares $119.41 million -5.2%19.4%16.6 $14.58 7/15/20218,640,000 shares $133.06 million +10.1%20.5%14.7 $15.40 6/30/20217,850,000 shares $134.78 million +1.7%18.6%9.8 $17.17 6/15/20217,720,000 shares $147.84 million +2.5%18.3%9.4 $19.15 5/28/20217,530,000 shares $138.33 million +3.9%17.9%8.8 $18.37 5/14/20217,250,000 shares $131.30 million -1.2%N/A7.7 $18.11 4/30/20217,340,000 shares $117.07 million +16.3%N/A7.9 $15.95 4/15/20216,310,000 shares $136.80 million -7.1%N/A7 $21.68 3/31/20216,790,000 shares $142.32 million +27.9%N/A10.1 $20.96 3/15/20215,310,000 shares $121.65 million +7.7%N/A7.4 $22.91 2/26/20214,930,000 shares $114.82 million No ChangeN/A7 $23.29 2/12/20214,930,000 shares $103.83 million +2.1%N/A7.5 $21.06 1/29/20214,830,000 shares $97.32 million -10.2%N/A7.1 $20.15 1/15/20215,380,000 shares $130.63 million -2.5%N/A7.3 $24.28 12/31/20205,520,000 shares $126.13 million +15.7%N/A7.7 $22.85 12/15/20204,770,000 shares $121.06 million +5.3%N/A7 $25.38 11/30/20204,530,000 shares $103.60 million -1.5%N/A7.3 $22.87 11/15/20204,600,000 shares $96.60 million +5.0%N/A9 $21.00 10/30/20204,380,000 shares $79.02 million -4.8%N/A9.3 $18.04 10/15/20204,600,000 shares $73.42 million +2.5%N/A12.6 $15.96 9/30/20204,490,000 shares $66.27 million +23.0%N/A14.8 $14.76 9/15/20203,650,000 shares $63.80 million +1.7%N/A11.3 $17.48 8/31/20203,590,000 shares $58.55 million +1.4%N/A11.4 $16.31 8/14/20203,540,000 shares $56.04 million +3.5%N/A9.1 $15.83 SNDX Short Interest - Frequently Asked Questions What is Syndax Pharmaceuticals' current short interest? Short interest is the volume of Syndax Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 23,690,000 shares of SNDX short. Learn More on Syndax Pharmaceuticals' current short interest. What is a good short interest ratio for Syndax Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SNDX shares currently have a short interest ratio of 11.0. Learn More on Syndax Pharmaceuticals's short interest ratio. Which institutional investors are shorting Syndax Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Syndax Pharmaceuticals: Simplex Trading LLC, Jane Street Group LLC, Caption Management LLC, Nomura Holdings Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Syndax Pharmaceuticals' short interest increasing or decreasing? Syndax Pharmaceuticals saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 23,690,000 shares, a decrease of 0.8% from the previous total of 23,870,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Syndax Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Syndax Pharmaceuticals: Merus N.V. (6.00%), Cytokinetics, Incorporated (13.64%), Akero Therapeutics, Inc. (10.24%), PTC Therapeutics, Inc. (7.28%), ADMA Biologics Inc (6.06%), ACADIA Pharmaceuticals Inc. (6.86%), Krystal Biotech, Inc. (10.85%), Vaxcyte, Inc. (10.49%), Arcellx, Inc. (15.24%), Lantheus Holdings, Inc. (12.25%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Syndax Pharmaceuticals stock? Short selling SNDX is an investing strategy that aims to generate trading profit from Syndax Pharmaceuticals as its price is falling. SNDX shares are trading down $0.24 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Syndax Pharmaceuticals? A short squeeze for Syndax Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SNDX, which in turn drives the price of the stock up even further. How often is Syndax Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNDX, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies MRUS Short Squeeze CYTK Short Squeeze AKRO Short Squeeze PTCT Short Squeeze ADMA Short Squeeze ACAD Short Squeeze KRYS Short Squeeze PCVX Short Squeeze ACLX Short Squeeze LNTH Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SNDX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.